Author

Dan Turner

INCREASING USE OF BIOLOGICS DID NOT REDUCE HOSPITALIZATION AND SURGERY RATES IN PAEDIATRIC IBD: A POPULATION-BASED STUDY FROM THE EPI-IIRN DATABASE
INCREASING USE OF BIOLOGICS DID NOT REDUCE HOSPITALIZATION AND SURGERY RATES IN PAEDIATRIC IBD: A POPULATION-BASED STUDY FROM THE EPI-IIRN DATABASE

Dan Turner  et al.

What to do if everything fails?
What to do if everything fails?

Dan Turner

Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis—An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition
Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis—An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition

Dan Turner  et al.

Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition
Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition

Dan Turner  et al.

Surgical Management of Crohn Disease in Children: Guidelines From the Paediatric IBD Porto Group of ESPGHAN
Surgical Management of Crohn Disease in Children: Guidelines From the Paediatric IBD Porto Group of ESPGHAN

Dan Turner  et al.

PHARMACOKINETICS, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PAEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
PHARMACOKINETICS, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PAEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY

Dan Turner  et al.

INTRODUCTION OF BOWEL ULTRASONOGRAPHY FOR FOLLOW-UP OF PEDIATRIC INFLAMMATORY BOWEL DISEASE: A SINGLE-CENTER EXPERIENCE
INTRODUCTION OF BOWEL ULTRASONOGRAPHY FOR FOLLOW-UP OF PEDIATRIC INFLAMMATORY BOWEL DISEASE: A SINGLE-CENTER EXPERIENCE

Dan Turner  et al.

VALIDATION OF GROWTH STUDY IN A PROSPECTIVE INCEPTION COHORT OF PEDIATRIC CD PATIENTS
VALIDATION OF GROWTH STUDY IN A PROSPECTIVE INCEPTION COHORT OF PEDIATRIC CD PATIENTS

Dan Turner  et al.

TASTY & HEALTHY IS A DIETARY APPROACH FOR INDUCING AND MAINTAINING REMISSION IN CROHN'S DISEASE: A PROSPECTIVE CASE SERIES
TASTY & HEALTHY IS A DIETARY APPROACH FOR INDUCING AND MAINTAINING REMISSION IN CROHN'S DISEASE: A PROSPECTIVE CASE SERIES

Dan Turner  et al.

REDUCED TREATMENT ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH DIABETES MELLITUS USING NEWER ANTI-DIABETIC MEDICATIONS: AN ANALYSIS FROM THE EPI-IIRN
REDUCED TREATMENT ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH DIABETES MELLITUS USING NEWER ANTI-DIABETIC MEDICATIONS: AN ANALYSIS FROM THE EPI-IIRN

Dan Turner  et al.

MORTALITY IN ELDERLY-ONSET INFLAMMATORY BOWEL DISEASES – A POPULATION-BASED STUDY FROM THE EPIDEMIOLOGICAL DATABASE OF THE ISRAELI IBD RESEARCH NUCLEUS (EPI-IIRN)
MORTALITY IN ELDERLY-ONSET INFLAMMATORY BOWEL DISEASES – A POPULATION-BASED STUDY FROM THE EPIDEMIOLOGICAL DATABASE OF THE ISRAELI IBD RESEARCH NUCLEUS (EPI-IIRN)

Dan Turner  et al.

EFFICACY AND SAFETY OF ADALIMUMAB IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF A RANDOMIZED-CONTROLLED PHASE 3 STUDY
EFFICACY AND SAFETY OF ADALIMUMAB IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF A RANDOMIZED-CONTROLLED PHASE 3 STUDY

Dan Turner  et al.

ENDOTROPHIN (PRO-C6) IS ASSOCIATED WITH MRE CONFIRMED INTESTINAL STRICTURES AND PROTEIN FINGERPRINT BIOMARKERS OF COLLAGEN DEGRADATION IS ASSOCIATED WITH ULCERATIONS IN PAEDIATRIC CROHN’S DISEASE PATIENTS – RESULTS FROM THE IMAGEKIDS STUDY
ENDOTROPHIN (PRO-C6) IS ASSOCIATED WITH MRE CONFIRMED INTESTINAL STRICTURES AND PROTEIN FINGERPRINT BIOMARKERS OF COLLAGEN DEGRADATION IS ASSOCIATED WITH ULCERATIONS IN PAEDIATRIC CROHN’S DISEASE PATIENTS – RESULTS FROM THE IMAGEKIDS STUDY

Dan Turner  et al.

PROTEIN FINGERPRINT ASSAYS REFLECTING NEUTROPHIL ACTIVITY, MUCOSAL DAMAGE, AND TISSUE FIBROSIS ARE SURROGATE BIOMARKERS FOR MUCOSAL HEALING IN PEDIATRIC CROHN’S DISEASE
PROTEIN FINGERPRINT ASSAYS REFLECTING NEUTROPHIL ACTIVITY, MUCOSAL DAMAGE, AND TISSUE FIBROSIS ARE SURROGATE BIOMARKERS FOR MUCOSAL HEALING IN PEDIATRIC CROHN’S DISEASE

Dan Turner  et al.

LONG-TERM OUTCOME OF VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE ASSOCIATED WITH PRIMARY SCLEROSING CHOLANGITIS: A MULTICENTER STUDY FROM THE PEDIATRIC IBD PORTO GROUP OF ESPGHAN
LONG-TERM OUTCOME OF VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE ASSOCIATED WITH PRIMARY SCLEROSING CHOLANGITIS: A MULTICENTER STUDY FROM THE PEDIATRIC IBD PORTO GROUP OF ESPGHAN

Dan Turner  et al.

PERIANAL CROHN'S DISEASE IN CHILDREN IS ASSOCIATED WITH MORE HOSPITALIZATIONS AND SURGERIES DESPITE HIGHER UTILIZATION OF IMMUNOMODULATORS AND BIOLOGICS: A REPORT FROM THE EPIIIRN COHORT
PERIANAL CROHN'S DISEASE IN CHILDREN IS ASSOCIATED WITH MORE HOSPITALIZATIONS AND SURGERIES DESPITE HIGHER UTILIZATION OF IMMUNOMODULATORS AND BIOLOGICS: A REPORT FROM THE EPIIIRN COHORT

Dan Turner  et al.

ASSOCIATION OF ANTIBIOTIC USE WITH DURABILITY OF BIOLOGIC AGENTS IN INFLAMMATORY BOWEL DISEASE: A REPORT FROM THE EPI-IIRN
ASSOCIATION OF ANTIBIOTIC USE WITH DURABILITY OF BIOLOGIC AGENTS IN INFLAMMATORY BOWEL DISEASE: A REPORT FROM THE EPI-IIRN

Dan Turner  et al.

THE ASSOCIATION OF INFLAMMATORY BOWEL DISEASE WITH CELIAC DISEASE AND CELIAC AUTOIMMUNITY, IN CHILDREN AND ADULTS: A NATIONWIDE STUDY FROM THE EPI-IIRN
THE ASSOCIATION OF INFLAMMATORY BOWEL DISEASE WITH CELIAC DISEASE AND CELIAC AUTOIMMUNITY, IN CHILDREN AND ADULTS: A NATIONWIDE STUDY FROM THE EPI-IIRN

Dan Turner  et al.

FECAL CALPROTECTIN AND DRUG LEVELS AT WEEK 14 PREDICT LONG-TERM RESPONSE OF VEDOLIZUMAB IN PAEDIATRIC INFLAMMATORY BOWEL DISEASES: A REPORT FROM THE PROSPECTIVE, MULTI-CENTRE VEDOKIDS STUDY
FECAL CALPROTECTIN AND DRUG LEVELS AT WEEK 14 PREDICT LONG-TERM RESPONSE OF VEDOLIZUMAB IN PAEDIATRIC INFLAMMATORY BOWEL DISEASES: A REPORT FROM THE PROSPECTIVE, MULTI-CENTRE VEDOKIDS STUDY

Dan Turner  et al.

Item 1 - 19 / 19
1